CANBRIDGE-B (01228) announced that its self-developed enzyme replacement therapy drug CAN 103 has been successfully included in China's first "Commercial Insurance Innovative Drug Directory," which will take effect on January 1, 2026. CAN 103, approved for market launch on May 13, 2025, is China's first domestically developed enzyme replacement therapy for long-term treatment of Type I and III Gaucher disease in patients aged 12 and above. It is also the first innovative biologic drug in China to pass segmented biologics production inspection.

On July 2, 2025, CAN 103 was first prescribed at Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, marking its official entry into clinical application. This is expected to significantly improve drug accessibility for domestic patients. The company views CAN 103's inclusion in the directory as a milestone achievement, as it ensures Gaucher disease patients can access safe and effective domestically produced enzyme replacement therapy with broader and more comprehensive treatment coverage.